Phenibut Overview, Dosing & Safety | Peptide Database

Phenibut (beta-Phenyl-GABA)

GABA-B Agonist | Anxiolytic & Sleep Aid

Community Research

Join others researching Phenibut — share findings, ask questions, and learn from real experiences

Phenibut (beta-phenyl-gamma-aminobutyric acid) is a synthetic GABA analog developed in the Soviet Union in the 1960s. It was designed to cross the blood-brain barrier, which GABA itself cannot do efficiently, by adding a phenyl ring to the GABA molecule. Phenibut has been prescribed in Russia and several former Soviet states since the 1960s for the treatment of anxiety, insomnia, post-traumatic stress disorder, vestibular disorders, and stuttering. It was famously included in the medical kit of Soviet cosmonauts for its calming effects without impairing cognitive performance. Phenibut is NOT approved by the FDA, EMA, or any Western regulatory agency as a pharmaceutical drug. In the United States, Australia, and parts of Europe, it has been sold as a dietary supplement or nootropic, though several countries have moved to restrict or ban its sale due to growing reports of dependence, withdrawal, and adverse events. The addiction and dependence potential of phenibut is HIGH, and tolerance develops rapidly with repeated use. This compound should be treated with the same caution as benzodiazepines or other GABAergic drugs.

Phenibut acts primarily as an agonist at GABA-B receptors, the same receptor target as baclofen (to which it is structurally related). GABA-B receptor activation inhibits neuronal excitability by opening potassium channels and reducing calcium influx at presynaptic terminals, leading to decreased neurotransmitter release and a net inhibitory effect on the central nervous system. This produces anxiolytic, sedative, and muscle-relaxant effects. In addition to GABA-B agonism, phenibut blocks voltage-dependent calcium channels (VDCCs), particularly alpha-2-delta subunit-containing channels, a mechanism shared with gabapentin and pregabalin. This contributes to its anxiolytic and analgesic properties. At higher doses, phenibut may also weakly stimulate GABA-A receptors, contributing to its sedative effects, though this is not its primary mechanism at typical doses. The R-enantiomer of phenibut is responsible for the majority of its GABA-B receptor activity, while the S-enantiomer is more selective for the alpha-2-delta VDCC subunit.

Molecular Data

Research Indications

Phenibut has been prescribed in Russia for anxiety disorders since the 1960s. Its GABA-B agonism and VDCC blockade produce meaningful anxiolytic effects. However, rapid tolerance development limits its utility for chronic anxiety management, and withdrawal can cause severe rebound anxiety.

One of the most commonly reported uses in non-prescription settings. Users report reduced social inhibition and increased verbal fluency. Effects are dose-dependent and tolerance develops very quickly, making this unsuitable for regular use.

Prescribed in Russia for sleep disturbances. Phenibut's GABAergic activity promotes sleep onset and may improve sleep architecture at moderate doses. As with all GABAergic sleep aids, rebound insomnia upon discontinuation can be severe.

Soviet-era research suggested phenibut could reduce the cognitive effects of stress without impairing performance, leading to its inclusion in cosmonaut medical kits. Limited modern controlled data supports this specific indication.

Prescribed in Russia for vertigo and vestibular dysfunction. The mechanism may involve GABA-B mediated inhibition of vestibular nuclei. Evidence is primarily from Russian-language clinical literature.

Some Russian clinical literature describes use in alcohol withdrawal protocols. This is a highly specialized application that requires medical supervision and is NOT recommended for self-treatment given phenibut's own severe dependence potential.

Dosing Protocols

Phenibut is taken orally, typically as a powder (hydrochloride salt or free amino acid form) in capsules or dissolved in water. The hydrochloride salt is acidic and can cause gastrointestinal irritation if taken on an empty stomach. Onset of effects is typically 1-2 hours after ingestion, with peak effects at 3-4 hours. Effects can last 5-8 hours depending on dose.

Anxiolytic - Low Dose

250-500 mg

Max 1-2x per week, never consecutive days

Oral (capsule or dissolved powder)

Sleep Aid

500-750 mg

Occasional use only, max 1x per week

Oral, taken 1-2 hours before bed

Anxiolytic - Moderate Dose

750-1000 mg

Interactions

What to Expect

Side Effects & Safety

Common Side Effects

Drowsiness and sedation, especially at higher doses

Dizziness and lightheadedness

Nausea and gastrointestinal discomfort (particularly with HCl form on empty stomach)

Tolerance develops rapidly, often within 2-3 days of consecutive use

Next-day grogginess or hangover-like effects

Headache

Stop Signs - Discontinue if:

Difficulty breathing or respiratory depression (especially if combined with other CNS depressants)

Loss of consciousness or inability to be roused

Severe confusion or delirium

Seizures (can occur during withdrawal from chronic use)

Suicidal ideation (reported during withdrawal)

Psychosis or hallucinations (reported during withdrawal from high-dose chronic use)

Contraindications

History of substance abuse or addiction (phenibut has high abuse potential)

Concurrent use of alcohol, benzodiazepines, GHB, barbiturates, or other CNS depressants

Renal impairment (phenibut is primarily excreted by the kidneys)

Pregnancy and breastfeeding (insufficient safety data)

History of seizure disorders (withdrawal may lower seizure threshold)

Current dependence on any GABAergic substance

Quality Checklist

Good Signs

White to off-white crystalline powder with slight acidic taste (HCl form)

Third-party tested with certificate of analysis (COA) showing purity above 99%

Clearly labeled with form (HCl or FAA), weight per capsule, and lot number

Purchased from a reputable vendor with transparent sourcing and testing

Properly sealed container with desiccant to prevent moisture absorption

Warning Signs

No certificate of analysis or third-party testing available

Purchased from unknown or unverified vendor

Powder appears clumpy, discolored, or has an unusual odor

Capsule weights are inconsistent (suggesting poor manufacturing)

Bad Signs

Product contains undisclosed additives or fillers

No labeling or lot number on packaging

Effects are inconsistent between batches from the same vendor

Product marketed with exaggerated claims about safety or lack of side effects

Any product that downplays or omits warnings about dependence and withdrawal

Frequently Asked Questions

What's the addiction risk of phenibut vs benzodiazepines?

Phenibut carries similar addiction and withdrawal risk to benzodiazepines despite not being a benzo. Physical dependence can develop in as little as 1-2 weeks of daily use, and withdrawal is severe -- including extreme anxiety, insomnia, tremors, and potentially life-threatening seizures. Withdrawal can last weeks to months. The key difference: phenibut has no real legitimate medical use anymore, making even occasional social use riskier than prescribed benzos.

Can I use phenibut once a week without problems?

Yes, 1x per week occasional use is the safest protocol and carries minimal dependence risk. However, once-per-week dosing still causes tolerance to build slightly, so many users find effectiveness diminishing by the 4th or 5th weekly dose. Most experienced users employ a 1-2x per month 'as-needed' protocol rather than consistent weekly dosing to preserve responsiveness and minimize any dependence risk.

Why is phenibut more dangerous than alcohol or cannabis?

Alcohol and cannabis don't cause the severe physical dependence seen with phenibut. Phenibut dependence develops faster (days to weeks), withdrawal is more dangerous (seizure risk), and withdrawal duration is longer (weeks to months). Combining phenibut with alcohol or other GABAergic drugs (benzodiazepines, GHB) creates extreme risk of respiratory depression, coma, and death -- this is not an exaggeration.

How do I safely discontinue phenibut if I've been using it regularly?

Do not stop abruptly -- this can trigger severe withdrawal. If you've used daily for more than a week, seek medical supervision for a slow taper, ideally using baclofen as a cross-taper agent (a GABA-B agonist like phenibut that doctors can manage safely). An even better approach is never to use phenibut daily in the first place, strictly limiting it to occasional 1-2x per week use from the start.

References

Comprehensive review of phenibut pharmacology by the researcher who contributed to its original development. Describes its GABA-B agonist activity, nootropic properties, and clinical use in Russia for anxiety, insomnia, PTSD, and vestibular disorders. Notes its favorable therapeutic index when used as prescribed in clinical settings.

Case report of phenibut dependence in a patient using escalating doses for self-medication of anxiety. Documented severe withdrawal symptoms including anxiety, tremor, and insomnia upon cessation. Highlights the lack of regulation and growing availability of phenibut as a supplement in Western countries.

Analysis of phenibut availability, user reports, and poison center data. Found widespread online availability with inconsistent labeling and dosing recommendations. Documented cases of acute toxicity including drowsiness, agitation, tachycardia, and reduced consciousness, particularly when combined with other substances.

Comparative study of phenibut and baclofen demonstrating that both compounds bind to GABA-B receptors with similar affinity. Phenibut also showed significant activity at voltage-dependent calcium channels. The R-enantiomer of phenibut was found to be the more pharmacologically active form at GABA-B receptors.

Clinical case series documenting phenibut withdrawal syndrome requiring hospitalization. Symptoms included visual and auditory hallucinations, psychomotor agitation, and tremor. Treatment with baclofen taper was effective. Authors recommend that clinicians become aware of phenibut as an increasingly common substance of abuse.

Disclaimer

This information is for educational and research purposes only. Consult a healthcare professional before use.